Syphilis Outbreaks in US Threatened by Drug Shortage

The United States is experiencing a surge in syphilis cases, including congenital syphilis, with 2021 reaching a 70-year high. However, a shortage of the main drug used in treatment, penicillin G benzathine (Bicillin L-A), is limiting access to treatment for those with the illness. The shortage is attributed to the rising number of syphilis cases and the drug's use as an alternative to amoxicillin, which is also in short supply. Pfizer, the sole manufacturer of penicillin G benzathine, estimates it will take about a year to increase production enough to end the shortage. Experts are concerned that the shortage could hinder patients' ability to receive treatment, and the CDC is recommending providers prioritize pregnant patients and infants while suggesting an alternate drug regimen for others.